Aditxt’s Subsidiary Adimune Highlights Its Approach to Reprogramming the Immune System Through DNA Instructions, Now with 96 Granted and 22 Pending Patents Targeting Autoimmunity Market Estimated at ...

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (NASDAQ: ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

In order to reprogram readily available cells into specific immune cells that fight various diseases, one must know the ...

As people grow older, their immune systems do not simply slow down, they often become locked into a simmering, ...

Cancer researchers have long treated genetic chaos and epigenetic rewiring as separate engines of disease, two parallel ...